lesigercept

Lesigercept (M8010) is a recombinant fusion protein that functions as a decoy receptor, or 'trap,' for interleukin-33 (IL-33). It is composed of the extracellular domain of the human IL-33 receptor (ST2) linked to the Fc portion of human immunoglobulin G1 (IgG1). By binding to circulating IL-33 with high affinity, lesigercept prevents the cytokine from interacting with its endogenous receptor complex (ST2 and IL-1RAcP), thereby blocking the activation of pro-inflammatory pathways associated with Type 2 immune responses. Maruho is currently evaluating lesigercept in Phase 2 clinical trials in Japan for the treatment of chronic spontaneous urticaria (CSU) in patients who are inadequately controlled by H1-antihistamines. The drug was originally developed by Chugai Pharmaceutical and subsequently licensed to Maruho for development and commercialization in the Japanese market.

Other names

lesigerceptumIL-33 trapIL33 trapIL 33 trapST2-Fc fusion proteinST-2-Fc fusion proteinST 2-Fc fusion protein